Tisagenlecleucel for treatment of children and young adults with
relapsed/refractory B cell acute lymphoblastic leukemia
Abstract
The treatment landscape for cancer therapy has changed drastically over
the past decade. Tisagenlecleucel, the first genetically engineered
adoptive cellular therapy approved by the United States Food and Drug
Administration, has revolutionized this field by demonstrating
impressive clinical success in children and young adults with
relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Now
three years since its approval, we have gained a deeper understanding on
the basic immunobiology and clinical efficacy of this drug. This review
will provide an updated summary of the clinical efficacy of
tisagenlecleucel in childhood and young adults with r/r B-ALL, common
side effects and their associated management strategies, as well as
barriers that remain to be addressed in order to realize the maximum
potential of this drug.